Skip to content

Study · Not a test of the peptide alone · 2018

5 results

Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.

Peterson SC, Barry AR

Current diabetes reviews1 Jan 2018Cited by 29 (Europe PMC)

PMID28413990 (opens in a new tab)DOI10.2174/1573399813666170414101450 (opens in a new tab)PepBankPUB-28413990
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists lowered the risk of all-cause mortality by 11% versus placebo.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class lowered the risk of death from any cause by 11% compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseAll-cause mortality
    Study

    n = 21,135

    Comparator
    Placebo
    Outcome group
    Mortality · Cardiovascular

    Measurements

    Risk ratio
    0.89 ratio
    all-cause mortality

    Source sentences

    Summary
    The risk of all-cause mortality was lowered by 11% in patients receiving a GLP1RA (RR 0.89, 95% CI 0.81-0.99).
    1 context sentence
    Summary · context
    EMBASE, MEDLINE, and CENTRAL were searched (inception to September 2016) for randomized, double-blind, placebo-controlled trials of at least one year in duration that compared any GLP1RA to placebo in patients with type 2 diabetes.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not significantly change cardiovascular death versus placebo.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class did not significantly change deaths from heart and blood vessel disease compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeCardiovascular death
    Study

    n = 21,135

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    There was no statistically significant difference between groups with respect to cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalizations for heart failure.
    1 context sentence
    Summary · context
    EMBASE, MEDLINE, and CENTRAL were searched (inception to September 2016) for randomized, double-blind, placebo-controlled trials of at least one year in duration that compared any GLP1RA to placebo in patients with type 2 diabetes.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not significantly change nonfatal myocardial infarction versus placebo.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class did not significantly change nonfatal heart attacks compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeNonfatal myocardial infarction
    Study

    n = 21,135

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    There was no statistically significant difference between groups with respect to cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalizations for heart failure.
    1 context sentence
    Summary · context
    EMBASE, MEDLINE, and CENTRAL were searched (inception to September 2016) for randomized, double-blind, placebo-controlled trials of at least one year in duration that compared any GLP1RA to placebo in patients with type 2 diabetes.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not significantly change nonfatal stroke versus placebo.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class did not significantly change nonfatal strokes compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeNonfatal stroke
    Study

    n = 21,135

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    There was no statistically significant difference between groups with respect to cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalizations for heart failure.
    1 context sentence
    Summary · context
    EMBASE, MEDLINE, and CENTRAL were searched (inception to September 2016) for randomized, double-blind, placebo-controlled trials of at least one year in duration that compared any GLP1RA to placebo in patients with type 2 diabetes.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not significantly change hospitalizations for heart failure versus placebo.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class did not significantly change hospital stays for heart failure compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeHospitalization for heart failure
    Study

    n = 21,135

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    There was no statistically significant difference between groups with respect to cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalizations for heart failure.
    1 context sentence
    Summary · context
    EMBASE, MEDLINE, and CENTRAL were searched (inception to September 2016) for randomized, double-blind, placebo-controlled trials of at least one year in duration that compared any GLP1RA to placebo in patients with type 2 diabetes.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.